06826 HAOHAI BIOTEC
- 30.700
- +0.100+0.33%
HAOHAI BIOTEC News
Haohai Biotech (688366): Short-term collection affects performance growth, optimistic about the future volume of “Haimei Yuebai”
[Brokerage Focus] Northeast Securities maintains a 'buy' rating for Haohai Biotech (06826), citing the potential annual increase in its market share.
Haohai Biotechnology (06826.HK): Domestic high-end hyaluronic acid leader, R&D innovation creates growth engine
Haohai Biotechnology (06826.HK): Hyaluronic acid maintains growth trend and looks forward to Haimei Yuebai's excellent performance
Haohai Biotech (688366): Short-term pressure in Q3 to focus on medical and aesthetic pipeline progress
Haohai Biotech (688366): Short-term procurement price conversion is gaining momentum; innovative varieties are worth looking forward to
Haohai Biotech (688366): Performance is in line with expectations, high growth in the medical and aesthetic hyaluronic acid business
Haohai Biotech (688366): Hyaluronic acid growth exceeds expectations, and the ophthalmology layout continues to be rich
Haohai Biotech (688366): Medicine and aesthetics continue to increase, and the localization process of ophthalmology accelerates
Haohai Biotech (688366): The 24H1 hyaluronic acid business continues to grow rapidly, and the research pipeline is rich in reserves
Haohai Biotech (688366): 24H1 performance is in line with expectations, focus on the new product Haimeiyue Baidu Sales
Haohai Biotech (688366) 2024 semi-annual report review: Hyaluronic acid maintains a high year-on-year growth trend, deducts non-profits and achieves steady growth
Haohai Biotech (688366): Innovative hyaluronic acid increased 51% year-on-year, and ophthalmology sales are gaining momentum
Haohai Biotech (688366) Company In-depth Research: Medicine and Aesthetics Drive Development Mergers and Acquisitions+Self-Research to Strengthen Competitive Advantages
Haohai Biotech (688366): The first quarter's performance grew rapidly, and the R&D pipeline continued to advance steadily
Haohai Biotech (688366): The performance is in line with expectations, and the medical, aesthetic and ophthalmology businesses are working together
Haohai Biotechnology (06826.HK): The Q1 profit side slightly exceeded expectations and the profitability was significantly optimized
Haohai Biotech (688366): Net profit after deducting non-return to mother increased 33%, expecting fourth-generation hyaluronic acid to be approved
Haohai Biotech (688366) First Coverage Report: Biomaterials Industry Leaders Build a Comprehensive Platform for Medical Devices+Medical and Aesthetic Consumption
Minsheng Securities released a research report on April 17 stating that it gave Haohai Biotech (688366.SH) a recommended rating. The main reasons for the rating include: 1) the company is a leader in the biomaterials segment, opening the development ceili
Analysis
Price Target
No Data
No Data